Clinical Scorecard: Intravenous Immunoglobulin as an Adjunct Therapy for Sepsis in Older Adults: A Randomized Controlled Trial Assessing Mortality, Organ Function, and Inflammatory Response

At a Glance

Key Highlights

• IVIG reduced 28-day mortality (18.3% vs. 31.7%; p = 0.043).
• SOFA scores declined more rapidly in the IVIG group (mean reduction at day 7: 3.7 vs. 2.1 points; p < 0.001).
• IVIG group had shorter ICU stay (9.8 vs. 12.4 days; p = 0.024) and duration of mechanical ventilation (4.2 vs. 5.7 days; p = 0.011).
• CRP and PCT levels decreased more substantially with IVIG.
• Adverse events were infrequent and comparable between groups.

Guideline-Based Recommendations

Diagnosis

• Use Sepsis-3 criteria for diagnosis in elderly patients.

Management

• Consider IVIG as an adjunct therapy to conventional treatment in elderly patients with sepsis.

Monitoring & Follow-up

• Monitor SOFA scores and inflammatory markers (CRP and PCT) during treatment.

Risks

• Be aware of potential hypersensitivity reactions to IVIG.

Patient & Prescribing Data

Elderly patients (≥65 years) with suspected sepsis.

IVIG administered at 0.4 g/kg/day for 3 days showed significant benefits in mortality and organ function.

Clinical Best Practices

• Incorporate immunomodulatory therapies like IVIG in treatment protocols for elderly sepsis patients.
• Utilize serial biomarker measurements alongside clinical endpoints to assess treatment efficacy.

Related Resources & Content

• Cochrane meta-analysis on IVIG in sepsis